86 related articles for article (PubMed ID: 19015435)
21. [Gefitinib as targeted treatment for non-small-cell lung cancer].
Knuuttila A; Karjalainen EM; Rouhos A; Mali P
Duodecim; 2005; 121(3):267-72. PubMed ID: 15787284
[No Abstract] [Full Text] [Related]
22. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
23. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
[TBL] [Abstract][Full Text] [Related]
27. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Ku GY; Haaland BA; de Lima Lopes G
Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
31. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Braiteh F; Kurzrock R; Johnson FM
J Clin Oncol; 2008 Jul; 26(20):3460-2. PubMed ID: 18612164
[No Abstract] [Full Text] [Related]
32. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B
J Clin Oncol; 2008 Jun; 26(16):2790-2. PubMed ID: 18509193
[No Abstract] [Full Text] [Related]
33. Erlotinib-induced bullous pemphigoid.
Stingeni L; Bianchi L; Minotti V; Lisi P
J Am Acad Dermatol; 2012 Nov; 67(5):e199-201. PubMed ID: 23062911
[No Abstract] [Full Text] [Related]
34. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Pascual JC; Belinchón I; Sivera F; Yuste A
Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
[No Abstract] [Full Text] [Related]
35. [Gefitinib therapy in non-small-cell lung cancer].
Jänne PA
Duodecim; 2005; 121(3):249-51. PubMed ID: 15787283
[No Abstract] [Full Text] [Related]
36. Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
Toda N; Fujimoto N; Kato T; Fujii N; Nakanishi G; Nagao T; Tanaka T
Dermatology; 2012; 225(1):18-21. PubMed ID: 22922680
[TBL] [Abstract][Full Text] [Related]
37. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
[No Abstract] [Full Text] [Related]
38. An acneiform eruption due to erlotinib: prognostic implications and management.
Journagan S; Obadiah J
J Am Acad Dermatol; 2006 Feb; 54(2):358-60. PubMed ID: 16443077
[No Abstract] [Full Text] [Related]
39. Letter to the editor. Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor.
Chen G; Zhang L; Wang Y; Guo Y; Liu H; Li Z
Rapid Commun Mass Spectrom; 2013 May; 27(10):1168-72. PubMed ID: 23592122
[No Abstract] [Full Text] [Related]
40. Adjuvant use of epidermal growth factor receptor kinase inhibitors may prevent bone metastases in patients with non-small cell lung carcinoma.
Dizdar O; Harputluoglu H; Dede DS; Altundag K
J Thorac Oncol; 2007 Dec; 2(12):1136. PubMed ID: 18090592
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
